Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients

Amikacin is commonly used for probabilistic antimicrobial therapy in critically ill patients with sepsis. Its narrow therapeutic margin makes it challenging to determine the right individual dose that ensures the highest efficacy target attainment rate (TAR) in this setting. This study aims to devel...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Boidin, Clément, Bourguignon, Laurent, Cohen, Sabine, Roger, Claire, Lefrant, Jean-Yves, Roberts, Jason A., Allaouchiche, Bernard, Lepape, Alain, Friggeri, Arnaud, Goutelle, Sylvain
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2019
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6811403/
https://ncbi.nlm.nih.gov/pubmed/31481443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00993-19
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars